Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints
- PMID: 35367118
- DOI: 10.1016/j.semcancer.2022.03.015
Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints
Abstract
Small cell lung cancer (SCLC) is a clinically common malignant tumor originating from the lung neuroendocrine stem cells, which has a poor prognosis and accounts for approximately 15% of all lung cancer cases. However, research on its treatment has been slow, and the 5-year survival rate of patients with SCLC has been < 5% for many years. In recent years, the development and popularization of gene sequencing technology have facilitated the understanding of the gene mutation landscape and tumor evolution of SCLC, thereby leading to a more accurate prediction of the prognosis of SCLC and the development of individualized treatment. In this review, we aimed to discuss the mutation evolution of SCLC from the perspective of a tumor evolution theory and described the sequence of mutation evolution in the occurrence and development of SCLC. In addition, we summarized the existing whole-exome sequencing (WES) data of SCLC cases at our center along with relevant publications on sequencing. Thereafter, we discuss the role of different mutated pathways in the occurrence of SCLC to predict its prognosis more accurately and summarized individualized treatment strategies.
Keywords: Narrative review; SCLC; Sequencing; Tumor evolution.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Similar articles
-
Molecular subtyping of small cell lung cancer.Semin Cancer Biol. 2022 Nov;86(Pt 2):450-462. doi: 10.1016/j.semcancer.2022.05.010. Epub 2022 May 21. Semin Cancer Biol. 2022. PMID: 35609720 Review.
-
DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer.Aging (Albany NY). 2020 Jan 20;12(2):1285-1303. doi: 10.18632/aging.102683. Epub 2020 Jan 20. Aging (Albany NY). 2020. PMID: 31959735 Free PMC article.
-
Novel prognostic biomarkers in small cell lung cancer reveal mutational signatures, genomic mutations, and immune implications.Sci Rep. 2025 May 4;15(1):15592. doi: 10.1038/s41598-025-00222-z. Sci Rep. 2025. PMID: 40320401 Free PMC article.
-
Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.J Thorac Oncol. 2013 Oct;8(10):1265-71. doi: 10.1097/JTO.0b013e3182a407fa. J Thorac Oncol. 2013. PMID: 24457237
-
Origins, genetic landscape, and emerging therapies of small cell lung cancer.Genes Dev. 2015 Jul 15;29(14):1447-62. doi: 10.1101/gad.263145.115. Genes Dev. 2015. PMID: 26220992 Free PMC article. Review.
Cited by
-
Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer.Front Pharmacol. 2023 Feb 15;14:1132158. doi: 10.3389/fphar.2023.1132158. eCollection 2023. Front Pharmacol. 2023. PMID: 36874015 Free PMC article. Review.
-
Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects.Front Pharmacol. 2022 Sep 1;13:970324. doi: 10.3389/fphar.2022.970324. eCollection 2022. Front Pharmacol. 2022. PMID: 36120311 Free PMC article.
-
Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer.Oncologist. 2023 Nov 2;28(11):e1052-e1064. doi: 10.1093/oncolo/oyad193. Oncologist. 2023. PMID: 37399175 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical